



 Cite this: *RSC Adv.*, 2024, 14, 5435

One-pot synthesis of 4-pyrimidone-2-thioether through base/acid-mediated condensation of *S*-alkylisothiourea and β -ketoester†

 Zhichao Lu,¹ ^{*,a} Tsung-Yun Wong,^a Yonghong Gan,^a Guihui Chen,^b Dinesh J. Paymode^a and Cheng-yi Chen^{*,a}

4-Pyrimidone-2-thioethers can be useful synthetic precursors to densely functionalized pyrimidines, commonly encountered in bioactive molecules. A convenient one-pot access to 4-pyrimidone-2-thioethers is reported herein, which utilizes a sequential base- and acid-mediated condensation of alkylisothioureas with β -ketoesters. Owing to mild reaction conditions, good to excellent functional group tolerance and yields are achieved. The utility of this approach is demonstrated by the synthesis of the crucial *adagrasib* intermediate on a 200 gram scale.

 Received 3rd January 2024
 Accepted 6th February 2024

DOI: 10.1039/d4ra00039k

rsc.li/rsc-advances

Introduction

A pyrimidine ring is a staple of many naturally occurring, bio-relevant molecules and a common feature in various other biologically active compounds.^{1,2} 4-Pyrimidone-2-thioether serves as a versatile building block for the introduction of a pyrimidine ring and further chemical modifications in the syntheses of these biologically active compounds. In particular, it enables regioselective functionalization of the 2-position over the more reactive 4-position.^{3,4} For instance, with the 4-hydroxy group intact, the alkylthio at the 2-position can either serve as a linker to another moiety, or a latent sulfone for Nucleophilic Aromatic Substitution (S_NAr). The 4-position can serve as a handle to introduce other moieties by ether formation or *via* an activation/ S_NAr sequence. One good example is the synthesis of *adagrasib* which is an oral, highly selective, and potent covalent KRAS^{G12C} inhibitor drug (Fig. 1) for patients with non-small cell lung cancer (NSCLC).^{4,5} Installation of a prolinol on the 2-position followed with the functionalized piperazine side chain on its 4-position was achieved, which avoided expensive palladium catalysis and protecting group manipulations.² Selected examples with 2,4-functionalized pyrimidine, as shown in Fig. 1, include Rilpivirine as a non-nucleoside reverse transcriptase inhibitor for the prevention and treatment of HIV infection,⁶ Cerdulatinib as a SYK/JAK kinase inhibitor for the treatment of peripheral T-cell lymphoma;⁷ Revaprazan as an acid pump antagonist for the treatment of gastritis,^{8,9} Surufatinib as a tyrosine kinase inhibitor for the treatment of

pancreatic and neuroendocrine tumor,¹⁰ and RK-287107 as a tankyrase inhibitor for colorectal cancer treatment.¹¹ We envisioned that an efficient synthesis of 4-pyrimidone-2-thioether could significantly simplify access to these bioactive molecules and hence facilitate the discovery of new pyrimidine-containing drugs.

The synthesis of 4-pyrimidone-2-thioether is typically achieved by a sequential β -ketoester condensation with thiourea and alkylation of thiol (Scheme 1A).^{12–15} This method usually affords high yields, but necessitates two chemical steps and is prone to overalkylation leading to the dialkyl impurity.⁴ Alternatively, the direct condensation of *S*-alkylisothiourea with β -ketoester leads to the desired 4-pyrimidone-2-thioether.^{4,11,16–19} This method takes advantage of commercial availability and





Fig. 1 Approved or investigational drugs containing 2,4 functionalized pyrimidine core.

^aMirati Therapeutics, San Diego, California, 92121, USA. E-mail: luz@mirati.com

^bPharmaBlock (USA), Inc., 777 Schwab Road, Unit D, Hatfield, Pennsylvania 19440, USA

 † Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra00039k>





Scheme 1 General methods for 4-pyrimidone 2-thioether synthesis.

easy access to many *S*-alkylisothioureas. However, the harsh reaction conditions with strong base and heating often cause *S*-alkylisothiourea degradation to side products and pungent thiol further complicates the workup (Scheme 1B). Herein, we wish to report a one-pot base/acid-promoted *S*-alkylisothiourea and β -ketoester condensation as an alternative method to circumvent the aforementioned issues with the existing approaches to 4-pyrimidone-2-thioether synthesis (Scheme 1C).

Results and discussion

During our synthesis of the key intermediate **3** for *adagrasib* 2nd generation process,⁴ a conventional two-step β -ketoester/thiourea condensation/alkylation was initially pursued, resulting in **3** in 76% overall yield. Nevertheless, this approach generated 2,4-bis-isopropylated side-products (~2%) which proved difficult to purge in the downstream process. To address these issues, a base-initiated condensation of *S*-isopropyl isothiourenium iodide **2** with β -ketoester **1** was explored, which led to discovery of a one-pot two-step sequence synthesis offering comparable yield (Scheme 2A). However, this route still suffered from the generation of a significant amount of impurities (~10%) including pungent 2-propanethiol. In addition, this process calls for solvent swap between two stages. With continuous efforts to improve the synthesis of this key intermediate, we found that the issues can be addressed by simple substitution of the base with acid at the stage 2, this one-pot protocol helped to avoid the solvent swap and significantly improved the yield (Scheme 2B). Given the advantages of this new approach, we explored its generality and reported herein a more efficient protocol for the synthesis of a wide variety of 4-pyrimidone-2-thioethers.

Scheme 2 A case study of 4-pyrimidone-2-thioether derivative **3** synthesis.


The optimization started with β -ketoester **1** and simple *S*-methylisothiourenium salts (Table 1). The counter anion of *S*-methylisothiourenium salts have substantial impact on the solubility. The most soluble iodide salt led to highest conversions (entries 1–5). Either TEA or DIPEA can be used as base (entries 6–8, base screen in ESI). To drive the reaction to completion, 1.1 equiv. DIPEA was sufficient (entry 1 vs. entries 9 and 10). Tetrahydrofuran (THF), dioxane, acetonitrile (ACN) and 2-methyltetrahydrofuran (2-MeTHF, entries 11–13) were all viable as the reaction solvents. 2-Methyltetrahydrofuran presented an advantage of a facile removal of water-soluble byproducts during work-up. On the other hand, undesirable oiling-out during workup was observed using methyl *tert*-butyl ether (MTBE) or toluene (see ESI†). Reactions proceeded well at -10 to -25 °C. The intermediate was readily formed in 3 h and found stable at 0 °C for at least 18 h, which grants operational flexibility between stages 1 and 2. For stage 2, weak acids such as acetic acid were not able to drive the reaction to completion. Strong acids such as TFA, HCl, MsOH, and TFOH substantially improved the conversion to the desired product. However, gummy material was observed upon working up all the reactions except the ones mediated by TFOH (1 equiv.). The reaction is optimally performed at 50 °C and reaches completion in 3–5 h (see ESI†).

Table 1 Reaction condition optimization^a

Entry	Stage	X ⁻	Base/acid	Solvent	int : 1 : 3a ^b (%)
1	Stage 1	I ⁻	DIPEA	2-MeTHF	94.4 : 0.5 : 5.1
2		Br ⁻	DIPEA		25.2 : 71 : 3.6
3		Cl ⁻	DIPEA		5.6 : 94.3 : 0
4		MsO ⁻	DIPEA		0 : 100 : 0
5		SO ₄ ²⁻	DIPEA		0 : 100 : 0
6 ^c	Stage 2	I ⁻	DIPEA		92.2 : 1.3 : 6.6
7			TEA		89.9 : 7.3 : 2.7
8			Pyridine		0 : 100 : 0
9 ^d			DIPEA		87.6 : 7.6 : 5.4
10 ^e			DIPEA		65.6 : 28 : 6.7
11			DIPEA	THF	92.6 : 2.6 : 4.8
12			DIPEA	Dioxane	87.0 : 6.8 : 6.3
13			DIPEA	ACN	90.5 : 2.0 : 7.3
14	Stage 2		AcOH	2-MeTHF	93 : 1.6 : 5.4
15			TFA		0 : 22.6 : 46.9
16			HCl		0 : 0 : 61
17			MsOH		0 : 8.2 : 65.5
18			TFOH		0 : 0 : 78.4

^a Unless otherwise noted, stage 1 were conducted with ketoester (0.5 mmol), *S*-methylisothiourea (0.55 mmol), and base (0.55 mmol) in 2-MeTHF (1.5 mL) at 0 °C for 3 hours; for stage 2, acid was added to the stage 1 reaction mixture, using 1.1 equiv. DIPEA as the base and 2-MeTHF as the solvent, stirred at 50 °C for 5 hours. ^b HPLC area percentage. ^c isothiourea (1.5 equiv.) was applied. ^d DIPEA (2.0 equiv.) was applied. ^e DIPEA (3.0 equiv.) was applied.



Table 2 Substrate scope of *S*-alkylisothiouraea^a


Entry	R	Stage 2 (3A : 3B)	Isolated yield (%)
1	Me	78.4 : 14.7	69
2	Et	98.6 : 0.9	84
3	<i>n</i> -Pr	99.0 : 0.6	85
4	<i>i</i> -Pr	98.8 : 0	94
5	<i>n</i> -Bu	99.3 : 0.4	73
6	<i>sec</i> -Bu	97.2 : 0	91
7	<i>t</i> -Bu	34.9 : 62.9	n/a
8	Dodecyl	91.4 : 0	85
9	Cyclopentyl	98.7 : 0	87
10 ^b	Cyclohexyl	83.9 : 0	60
11 ^c	Ph	0 : 0	0
12 ^d	Bn	74.0 : 0	75


^a Unless otherwise noted, reactions were conducted as follows: to a solution of *S*-alkylisothiouronium iodide (1.1 equiv.) and β -ketoester (3.0–6.0 mmol, 1.0 equiv.) in 2-MeTHF (0.33 M with respect to ketoester) at 0 °C was added DIPEA (1.1 equiv.) dropwise. The reaction stirred at 0 °C for 18 hours and then was added with TfOH (1.0 equiv.) dropwise. The reaction was heated to 50 °C in 0.5 h and then stirred for 3–5 hours. ^b *S*-Cyclohexylisothiouronium bromide was applied. ^c Phenylisothiouronium degraded to urea at stage 1. ^d *S*-Benzylisothiouronium chloride was applied, and stage 1 was stirred at room temperature for 18 h.

With the optimized reaction conditions in hand, we explored the reaction scope of *S*-alkylisothiouraea (Table 2). Demethylation at stage 2 was observed when *S*-methylisothiouraea was employed (entry 1). We envisioned that increasing the size of the alkyl group in *S*-alkylisothiouronium iodides would prevent the dealkylation. Hence, a series of *S*-alkylisothiouronium iodides were prepared by reaction of thiourea and alkyl halides in the corresponding alcohols under reflux conditions (see ESI[†]). As expected, 0° (entry 1), 1° (entries 2, 3, 5, 8), and 2° *S*-alkylisothiouraea (entries 4, 6) displayed similar reactivity at stage 1, while dealkylation decreases significantly with increased bulkiness of the alkyl group (entry 1 vs. entries 2–4). However, dealkylation of 3° *S*-alkylisothiouraea (entry 7) still occurred *via* E₂ elimination at stage 1 and E₁ elimination at stage 2, respectively, which is in accordance with literature reports.^{20,21} It should be noted that reaction with *S*-benzylisothiouronium chloride, a readily available compound, also works given the stage 1 temperature was raised to room temperature. *S*-Isopropylisothiouronium iodide can be prepared in high yield and good quality. Based on these results, we selected *S*-isopropylisothiouronium iodide to further explore its condensation with β -ketoesters (entries 4).

Having identified *S*-isopropylisothiouraea and the optimal reaction conditions, we next explored the scope of the β -ketoester. As shown in Scheme 3, all the β -ketoesters afforded the


corresponding products in good to excellent yields. Substrates with less bulky alkoxy (OR³) and alkyl (R¹ and R²) gave much higher yields (entries 5a–5d; entries 5e–5h; entries 5i–5n). Aryl ketoester (R¹ = phenyl) did not give the desired product probably due to the bulkiness of the phenyl group. A wide range of functional groups such as ester (5t), ether (5q), amine (5r, 5s), alcohol (5y) were well tolerated in this protocol. When di- β -ketoester was applied (5u), double cyclization afforded bi-4-pyrimidone 2-thioether in 61% yield. Several cyclic β -ketoester were also tested and gave acceptable to excellent yields (5w, 5x, 5y). Obviously, acid-labile group like Boc- was deprotected under acidic condition at stage 2 (5aa), whereas other protecting groups such as Cbz- (5ac), Bn- (5ab, 5ad), remained intact.

The practicality of this novel method was tested in a large-scale synthesis of 3, a key intermediate in the synthesis of *adagrasib*. Delightfully, the compound 3 was obtained in 94%




Scheme 3 Substrate Scope of β -ketoester^a. ^a Unless otherwise noted, ethyl β -ketoester substrate were applied and reactions were conducted as follows: to a solution of *S*-alkylisothiouronium iodide (1.1 equiv.) and β -ketoester (3.0–6.0 mmol, 1.0 equiv.) in 2-MeTHF (0.33 M with respect to β -ketoester) at 0 °C was added DIPEA (1.1 equiv.) dropwise. The reaction stirred at 0 °C for 18 hours and then was added with TfOH (1.0 equiv.) dropwise. The reaction was heated to 50 °C in 0.5 h and then stirred for 3–5 hours. ^b 2-Acetylbutyrolactone was used as the starting material. ^c deBoc product was obtained.





Scheme 4 Large-scale synthesis and telescope.



Scheme 5 Plausible mechanism.

yield and 99.7% purity in the 200 gram scale reaction (Scheme 4A). Furthermore, the *S*-alkylisothioureia preparation and cyclization were telescoped to accomplish the one-pot synthesis of 3 in 92% yield (Scheme 4B).

As shown in Scheme 5, a plausible reaction mechanism was proposed. At stage 1, the condensation of isothioureia with β -ketoester affords **int A**, which readily cyclizes to give **int B**. The structure of **int B** was definitively confirmed by NMR analysis (see ESI[†]). At stage 2, cyclic aldol **int B** dehydration/aromatization mediated by acid, instead of base,^{22,23} leads to the desired 4-pyrimidone-2-thioether.

Conclusions

In summary, a one-pot, two-stage base/acid-mediated reaction of isothioureia and β -ketoester provided various 4-pyrimidone 2-thioether in good to excellent yields with broad functional group compatibility. The broad substrate scope takes advantage of readily available starting materials and mild reaction conditions. Importantly, this methodology has been applied to the large-scale syntheses of KRAS^{G12C} inhibitor *adagrasib* and can be readily extended to the synthesis of other bioactive molecules containing pyrimidine core.

Author contributions

ZCL, CYW, CYC directed the project. The experiments were conducted and characterized by ZCL, CYW, YHG, GHC, and DP. ZCL and CYC prepared the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors are grateful to Pharmablock US for the chemistry support. To Todd Baumgartner (Mirati Therapeutics) and Stanley Yu (Mirati Therapeutics) for the analytical support, To Aastha Chadha for the melting point test, and to Michał Achmatowicz (Mirati Therapeutics) for the helpful discussion during the preparation of the manuscript.

Notes and references

- A. M. Chiacchio, D. Iannazzo, R. Romeo, V. S. Giofrè and L. Legnani, *Curr. Med. Chem.*, 2019, **26**, 7166–7195.
- S. Nadar and T. Khan, *Chem. Biol. Drug Des.*, 2022, **100**, 818–842.
- C. Li, F. Haeffner, S. Wang, C. Yuan, D. Shang, X. Shi, B. Ma, B. T. Hopkins and E. M. O'Brien, *Org. Process Res. Dev.*, 2022, **26**, 137–143.
- C.-y. Chen, Z. Lu, T. Scattolin, C. Chen, Y. Gan and M. McLaughlin, *Org. Lett.*, 2023, **25**, 944–949.
- J. B. Fell, J. P. Fischer, B. R. Baer, J. F. Blake, K. Bouhana, D. M. Briere, K. D. Brown, L. E. Burgess, A. C. Burns, M. R. Burkard, H. Chiang, M. J. Chicarelli, A. W. Cook, J. J. Gaudino, J. Hallin, L. Hanson, D. P. Hartley, E. J. Hicken, G. P. Hingorani, R. J. Hinklin, M. J. Mejia, P. Olson, J. N. Otten, S. P. Rhodes, M. E. Rodriguez, P. Savechenkov, D. J. Smith, N. Sudhakar, F. X. Sullivan, T. P. Tang, G. P. Vigers, L. Wollenberg, J. G. Christensen and M. A. Marx, *J. Med. Chem.*, 2020, **63**, 6679–6693.
- I. Usach, V. Melis and J.-E. Peris, *J. Int. AIDS Soc.*, 2013, **16**, 18567.
- C. Ishikawa, M. Senba and N. Mori, *Int. J. Oncol.*, 2018, **53**, 1681–1690.
- K.-S. Yu, K.-S. Bae, J.-H. Shon, J.-Y. Cho, S.-Y. Yi, J.-Y. Chung, H.-S. Lim, I.-J. Jang, S.-G. Shin, K.-S. Song and B.-S. Moon, *J. Clin. Pharmacol.*, 2004, **44**, 73–82.
- H.-K. Kim, S.-H. Park, D.-Y. Cheung, Y.-S. Cho, J.-I. Kim, S.-S. Kim, H.-S. Chae, J.-K. Kim and I.-S. Chung, *J. Gastroenterol. Hepatol.*, 2010, **25**, 1618–1625.
- A. Koumariou and G. Kaltsas, *Nat. Rev. Endocrinol.*, 2021, **17**, 9–10.
- F. Shirai, T. Tsumura, Y. Yashiroda, H. Yuki, H. Niwa, S. Sato, T. Chikada, Y. Koda, K. Washizuka, N. Yoshimoto, M. Abe, T. Onuki, Y. Mazaki, C. Hiramata, T. Fukami, H. Watanabe, T. Honma, T. Umehara, M. Shirouzu, M. Okue, Y. Kano, T. Watanabe, K. Kitamura, E. Shitara, Y. Muramatsu, H. Yoshida, A. Mizutani, H. Seimiya, M. Yoshida and H. Koyama, *J. Med. Chem.*, 2019, **62**, 3407–3427.
- J.-B. Wang, M.-D. Ma, N. Lu, Y.-Z. Yang, J.-X. Yang, Y.-M. Li, C.-Q. Xie, N.-Y. Ma, R.-H. Luo, Y.-P. Wang, L.-M. Yang, H.-B. Zhang, Y.-T. Zheng and Y.-P. He, *Drug Dev. Res.*, 2023, **84**, 465–474.



- 13 R.-M. Rui, C.-R. Tang, C.-T. Zhang, W.-K. Pan, K. Gan, R.-H. Luo, Z.-Q. Wei, F.-S. Jing, S.-M. Huang, L.-M. Yang, Y.-M. Li, Y.-P. Wang, W.-L. Xiao, H.-B. Zhang, Y.-T. Zheng and Y.-P. He, *Bioorg. Chem.*, 2022, **119**, 105494.
- 14 D. Wu, Y. Feng, H. Wang, J. Yang, X. Chen, Y. Wang, C. Cong Lai, Y. Zhang, C. Li, X. Xia and Y. He, *Med. Chem. Res.*, 2017, **26**, 1388–1396.
- 15 C. Tintori, A. Brai, M. C. Dasso Lang, D. Deodato, A. M. Greco, B. M. Bizzarri, L. Cascone, A. Casian, C. Zamperini, E. Dreassi, E. Crespan, G. Maga, G. Vanham, E. Ceresola, F. Canducci, K. K. Ariën and M. Botta, *J. Med. Chem.*, 2016, **59**, 2747–2759.
- 16 S. Pochampally, K. L. Hartman, R. Wang, J. Wang, M.-K. Yun, K. Parmar, H. Park, B. Meibohm, S. W. White, W. Li and D. D. Miller, *ACS Pharmacol. Transl. Sci.*, 2023, **6**, 526–545.
- 17 Z. Wang, W. A. Zalloum, W. Wang, X. Jiang, E. De Clercq, C. Pannecouque, D. Kang, P. Zhan and X. Liu, *J. Med. Chem.*, 2021, **64**, 13658–13675.
- 18 B. Selvakumar, N. Gujjar, M. Subbiah and K. P. Elango, *Med. Chem. Res.*, 2018, **27**, 512–519.
- 19 V. M. Alford, A. Kamath, X. Ren, K. Kumar, Q. Gan, M. Awwa, M. Tong, M. A. Seeliger, J. Cao, I. Ojima and N. S. Sampson, *ACS Chem. Biol.*, 2017, **12**, 2788–2803.
- 20 N. F. Haley and M. W. Fichtner, *J. Org. Chem.*, 1980, **45**, 175–177.
- 21 Y. El-Ahmad and P. Reynaud, *J. Heterocycl. Chem.*, 1988, **25**, 711–714.
- 22 H. L. Wheeler and H. F. Merriam, *Am. Chem. J.*, 1903, **29**, 478–492.
- 23 J. B. Campbell and J. W. Firor, *J. Org. Chem.*, 1995, **60**, 7687–7689.

